Research library

Key finding

In randomized paediatric studies, weekly PEGylated rhGH increased annualized height velocity to 13.41 cm per year and was non-inferior to daily rhGH, with comparable adverse-event rates.

Key finding

In adults with HIV-associated abdominal obesity, rhGH reduced visceral fat by 22.7% over 12 weeks versus 1.9% in controls, while glucose measures worsened in the rhGH arm.

Key finding

Growth hormone did not accelerate healing across all tibial fractures, but the prespecified closed-fracture subgroup healed in a median 95 days versus 129 days with placebo.

Key finding

In children dependent on parenteral nutrition for short-bowel syndrome, growth hormone did not significantly improve weaning from parenteral nutrition compared with standard care.

Key finding

Five years of continuous growth-hormone treatment improved height standard-deviation scores in children born small for gestational age, with a larger response at the higher dose.

Key finding

The study reports that at 34 weeks, somapacitan significantly reduced truncal fat percentage (estimated difference: -1.53% [-2.68; -0.38]; P = 0.0090), demonstrating superiority compared with placebo, and it improved other body composition parameters (including visceral fat and lean body mass) and IGF-I SDS.

Key finding

The study reports that height SDS improved from -3.24 at baseline with a significantly greater increase (estimated mean [95% confidence interval]) with 0.066 vs.

Key finding

The study reports that insulin-like growth factor-I SDS increased from -1.71 to -0.64 (0.033 mg/kg/day) and to 0.63 (0.066 mg/kg/day).

Key finding

The study reports that long-term, continuous GH treatment in children born SGA appears to be efficacious, associated with potential benefits for several metabolic parameters and associated with no long-term safety concerns.

Key finding

The study reports that gH replacement decreased visceral adipose tissue, increased fat-free mass, decreased hsCRP, and improved quality of life in patients with GHD after cure of acromegaly, with minimal side effects and without an increase in insulin resistance.

Key finding

The study reports that gH treatment was associated with increased thymic mass.

Key finding

The study reports that fasting glucose and insulin levels increased during GH treatment but recovered after discontinuation.

Key finding

The study reports that no significant acceleration of bone age or side effects related to treatment was seen.

Key finding

The study reports that the study showed that hGH treatment increased LBM significantly at all dosage levels (2.5 kg [95% confidence interval 1.8 to 3.1] versus -0.4 kg [95% confidence interval -1.4 to 0.6]; P < 0.001 for pooled hGH groups versus placebo).

Key finding

The study reports that no significant differences were noted between X(maternal) and X(paternal) subjects for parents' heights, birth weight and length, and height, age, or bone age at study entry.

Key finding

The study reports that this is the first evidence from a randomized, controlled trial to adult height that GH supplementation with induction of puberty at a near physiological age increases the adult height of girls with Turner syndrome.

Key finding

The study reports that it is likely, however, that GH and estrogen treatment improved psychosocial functioning.

Key finding

The study reports that after discontinuation of GH treatment, fasting insulin levels returned to pretreatment levels (8.4 mU/liter), whereas the 120-min area under the curve for insulin decreased, compared with 6-yr levels (P < 0.01), regardless of GH dosage group.

Key finding

The study reports that after starting estrogen treatment, the decrease in height velocity (HV) changed significantly to a stable HV, without affecting bone maturation (change in bone age/change in chronological age).

Key finding

The study reports that seventeen of the 54 children were partially GH deficient (stimulated GH peak, 10-20 mU/liter).